Physician profile
Sara Lynn Borcherding
NPI 1831113885
$1,396.27
in general payments reported to CMS, 2019-2025
14 companies · $305 in 2025
The $305 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.37 · 2020: $423 · 2021: $138 · 2023: $264 · 2024: $220 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $729.68 | 2019-2025 | Grafix Pl, Oasis, Stravix Pl |
| Organogenesis INC. | $154.15 | 2021-2025 | Puraply, Affinity |
| Astrazeneca Pharmaceuticals LP | $124.89 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $118.13 | 2020 | |
| Cashflow Solutions, LLC | $54.81 | 2023-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Convatec INC. | $44.20 | 2019-2021 | |
| Ovik Health, LLC | $36.12 | 2020 | |
| Paratek Pharmaceuticals, INC. | $34.28 | 2021-2024 | Nuzyra |
| Reprise Biomedical, INC. | $23.22 | 2025 | Miro3d |
| Coloplast Corp | $22.77 | 2025 | |
| Solventum Corporation | $18.37 | 2024 | Activ.A.C. |
| Merck Sharp & Dohme LLC | $17.94 | 2025 | Zerbaxa |
| Kci USA, INC. | $12.90 | 2020 | |
| Next Science LLC | $4.81 | 2023 | Surgx, Blastx, Xperience |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Borcherding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.